February 2023
PDR Drug Update
- Lead Story
- Latest FDA News
- FDA Recalls
- Labeling Updates
Combating Recurrent CDI with First-in-Class Live Biotherapeutic
Dysbiosis, or the imbalance of the microbiome of the gut, may lead to illness in patients, which can be severe. Antibiotics are common culprits of causing this imbalance since both good and bad bacteria are affected during treatment. If a patient carries or is exposed to C. difficile spores, the opportunistic bacteria could take hold and cause an infection. This risk is greater with courses of antibiotics, hospitalizations, or older individuals. Some indicators of CDI are diarrhea, nausea, pain, and potentially colitis. In cases of more severe infection, additional complications and disease can result, including dehydration, kidney failure, toxic megacolon, sepsis, and even death. Treatment for CDI can be complicated and lengthy and may only provide a temporary resolution. Up to 30% of individuals who experience CDI develop a recurrent case. As incidences of CDI repeat in a patient, the likelihood of future recurrences increases, putting further stress on their already greatly taxed health.
The standard approach to treatment of severe CDI includes vancomycin, which is bactericidal and effective for gram-positive bacteria. It alters the bacterial cell wall and results in cell death. For recurrent CDI, antibody-based therapy is introduced, using Zinplava (bezlotoxumab), which interferes with the protein toxin production of C. difficile. Fidaxomicin is also used in recurrent CDI, another bactericide for C. difficile. Unfortunately, even with repeated targeted treatments, CDI may not be eradicated, and a patient may continue to have recurrences. In order to disrupt the excruciating cycle in patients, clinical measures may need to be taken to correct the dysbiosis through the introduction of a biotherapeutic. However, until recently, there has not been a standardized therapeutic option for gut microbiome restoration. The new FDA approval for Rebyota (fecal microbiota, live-jslm) opens the pathway for providing regulated access to treatment that offers a sustained improvement in prevention of recurrent CDI.
Rebyota is indicated for the prevention of recurrence of CDI in individuals aged 18 years and older, following antibiotic treatment for recurrent CDI. The treatment consists of a single 150mL rectal dose of a microbiota suspension. The fecal microbiota in Rebyota includes Bacteroides, which are beneficial bacteria that assist in the needed diversity in the gut microbiome. Only qualified human donors supply the pathogen-tested fecal matter used to manufacture Rebyota. Screening for potential donors includes blood and stool testing to identify and prevent inclusion of any detrimental bacteria, parasites, or viruses. In clinical trial, 90% of patients with treatment success at the eight-week primary endpoint still experienced a continued outcome of no recurrent CDI for six months. These are encouraging results and showcase the benefit of using microbiota-based therapy.
Stay informed about emergent drug information, including gastroenterology therapeutics, by updating or registering your profile to receive email alerts and other critical drug information updates from PDR. You can also stay current by using the official PDR app, mobilePDR, available for free from your favorite app stores.
FDA New Approvals
Brenzavvy
The FDA has approved Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 inhibitor. Brenzavvy is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Learn more about Brenzavvy
Jaypirca
The FDA has approved Jaypirca (pirtobrutinib) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Learn more about Jaypirca
Jesduvroq
The FDA has approved Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the once-a-day treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months. Learn more about Jesduvroq
Orserdu
The FDA has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Learn more about Orserdu
Rykindo
The FDA has approved Rykindo (risperidone) extended-release injectable suspension, for intramuscular use, for treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder in adults. Learn more about Rykindo
FDA New Indications
Brukinsa
The FDA has approved Brukinsa (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This is the fourth approved indication for Brukinsa. Learn more about Brukinsa
Keytruda
The FDA has approved Keytruda (pembrolizumab) for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4cm), II, or IIIA non-small cell lung cancer (NSCLC). This approval marks the fifth indication for Keytruda-based regimens in NSCLC and the 34th indication for Keytruda in the US. Learn more about Keytruda
Revatio
The FDA has approved Revatio (sildenafil) for the treatment of pulmonary arterial hypertension (WHO Group I) in pediatric patients (age 1 to 17 years) to improve exercise ability and, in pediatric patients too young to perform standard exercise testing, pulmonary hemodynamics thought to underly improvements in exercise. Learn more about Revatio
Tukysa
The FDA has approved Tukysa (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Learn more about Tukysa
FDA New Dosing
Tezspire
The FDA has approved Tezspire (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. Tezspire is the only biologic approved for severe asthma with no phenotype (eg, eosinophilic or allergic) or biomarker limitation within its approved label. Learn more about Tezspire
FDA Recalls
Edgewell Personal Care Company Banana Boat Sunscreen
Edgewell Personal Care Company expanded its voluntary nationwide recall of three batches of Banana Boat hair and scalp sunscreen spray SPF 30, to the consumer level. One additional batch has been added to the original recall announced on July 29, 2022. Learn more about the Edgewell Personal Care Company Banana Boat sunscreen recall
Ibsa Tirosint-Sol
IBSA Pharma Inc. is voluntarily recalling 27 lots of Tirosint-Sol (levothyroxine sodium) oral solution to the consumer level. This voluntary recall has been initiated because these lots may be subpotent. The company's analyses show a slight decrease below 95.0% of its labeled amount in levothyroxine sodium (T4) for some lots. Learn more about the Tirosint-Sol recall
Labeling Updates
- Key
-
Boxed Warning
-
Other Warnings*
*Warnings and Precautions; Adverse Reactions; Drug Interactions; and Contraindications
-
Updates to Indications/Dosage
-
Other Updates†
†Other labeling changes; added to PDR database
No Avycaz boxed warning | No Avycaz Indications/Dosage Updates | Avycaz (avibactam/ceftazidime) | ||
No Lo Loestrin Fe boxed warning | No Lo Loestrin Fe Other Warnings | No Lo Loestrin Fe Indications/Dosage Updates | Lo Loestrin Fe(ethinyl estradiol/ferrous fumarate/norethindrone acetate) | |
No Ozurdex boxed warning | No Ozurdex Other Warnings | No Ozurdex Indications/Dosage Updates | Ozurdex (dexamethasone) |
No Skyrizi boxed warning | No Skyrizi Other Warnings | No Skyrizi Indications/Dosage Updates | Skyrizi (risankizumab-rzaa) | |
No Vraylar boxed warning | Vraylar (cariprazine) |